Roche walks away from Repare solid tumor deal just weeks after $40M milestone payout
Roche has terminated its license agreement with Repare Therapeutics for the cancer drug camonsertib in a move described by analysts as “particularly strange” in light …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
